Clinical trial
Open Label Study of Subcutaneous Homoharringtonine (Omacetaxine Mepesuccinate)…
NCT00462943 · Teva Branded Pharmaceutical Products R&D, Inc., Industry · Completed
Key facts
| NCT number | NCT00462943 |
|---|---|
| Title | Open Label Study of Subcutaneous Homoharringtonine (Omacetaxine Mepesuccinate) in Patients With Advanced CML |
| Official title | A Phase II Open-Label Study of the Subcutaneous Administration of Homoharringtonine. (Omacetaxine Mepesuccinate; OMA) in the Treatment of Patients With Chronic Myeloid. Leukemia (CML) Who Have Failed or Are Intolerant to Tyrosine Kinase Inhibitor Therapy |
| Lead sponsor | Teva Branded Pharmaceutical Products R&D, Inc., Industry |
| Collaborators | Cephalon Industry ChemGenex Pharmaceuticals |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Chronic Myeloid Leukemia |
| Intervention type | Drug |
| Interventions | Omacetaxine mepesuccinate |
| Enrollment | 100 |
| Start date | Mar 7, 2007 |
| Primary completion | Aug 4, 2009 |
| Completion | Jun 27, 2013 |
| First posted | Apr 19, 2007 |
| Last update posted | Dec 28, 2021 |
| Countries | Canada, France, Germany, Hungary, India, Italy, Poland, Singapore, United Kingdom, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: